Tetra Bio-Pharma CSO Discusses Opportunities in Exclusive CFN Media Interview
Ryan Allway
July 26th, 2017
News, Top News
Tetra Bio-Pharma Inc. (CSE: TBP) (CN: TBP) (CNSX: TBP) (OTCQB: TBPMF) has made tremendous progress in advancing its clinical pipeline designed to bring innovative cannabis products to market. With a new CEO and new partnerships, these efforts could be accelerated over the coming quarters as the company gears up for pivotal Phase III clinical trials demonstrating the benefits of inhaled cannabis.
CFN Media’s Mike Elliott recently interviewed Tetra Bio-Pharma Chief Science Officer Dr. Guy Chamberland to discuss these developments in greater detail.
New Product & Research Partner
Tetra Bio-Pharma recently announced a letter of intent with Constance Therapeutics for the clinical development and commercialization of its medicinal cannabis extracts in Canada. Under the terms, the company will enter into a licensing agreement with Constance Therapeutics to perform clinical research on the novel cannabis extract products while bringing the products to market in Canada’s federally-legal medical cannabis industry.
Some studies have shown that cannabinoids may have the ability to reduce and inhibit tumor growth in various animal models. In addition, cannabinoids may enhance the effects of traditional cancer treatments with radiation therapy and help reduce the size of brain cancers – such as Glioma – compared to controls. The two companies aim to investigate this potential in a pharmaceutical-grade clinical trial environment.
Constance Therapeutics specializes in manufacturing cannabis products designed to enable medical professionals to offer patients a broader array of treatment options. In essence, the products fill the void between traditional pharmaceuticals and cannabis products sold in dispensaries by introducing a highly-controlled, quantitatively-defined, and patented process to ensure the highest quality product targeting specific goals.
“Constance Therapeutics works in conjunction with physicians and medical professionals to provide integrative medicinal options to those suffering from serious conditions, such as cancer, lyme, autoimmune, chronic pain, neurodegenerative diseases, and other out-of-option patients,” said Constance Therapeutics CEO Constance Finley in the press release announcing the deal. “The approach used by Constance Therapeutics is exactly the type of business model that Tetra is implementing to bring medical marijuana products to patients.”
Incoming CEO Targets Growth
Tetra Bio-Pharma recently appointed Bernard Fortier as Chief Executive Officer to help lead these efforts and other growth initiatives. Mr. Fortier has over two decades of international experience in management and business development within the biopharmaceutical industry. After graduating from Laval University, he spent five years in the United States working on business development and management before securing an MBA in 2001. He also brings experience and expertise in launching botanical and OTC drugs on the market as well as managing teams of sales representatives that promote products to physicians.
“I am very pleased to welcome Bernard to the team as our new CEO as we are focused on building Tetra as a leading bio-pharmaceutical organization,” said departing interim CEO Andre Rancourt. “Bernard is an experienced leader and executive with proven skills in leadership, strategy, and execution, as well as business development and negotiation. Going forward, we will be placing considerable efforts in expanding Tetra in the U.S. market.”
The company’s PPP001 aims to become the first cannabis inhalation product designed to help patients suffering from advanced cancer pain. After receiving positive safety data, the company is working with experts at Sante Cannabis to design a Phase III clinical trial expected to launch by the fourth quarter of this year or the first quarter of next year. The goal is to support traditional forms of cannabis consumption with rigorous scientific data.
Early data from smokable cannabis studies have shown that it may perform better than synthetic cannabinoids in treating various medical conditions. Researchers believe that this may be due to the so-called ‘entourage effect’ that cannabinoids have with each other. With hundreds of cannabinoids in the cannabis plant, these researchers believe that there’s much more than just tetrahydrocannabinol (THC) and cannabidiol (CBD) when it comes to medical benefit.
Looking Ahead
Tetra Bio-Pharma Inc. (CSE: TBP) (CN: TBP) (CNSX: TBP) (OTCQB: TBPMF) represents a compelling investment opportunity within the cannabis industry. With its recent letter of intent, the company is well-positioned to bring promising therapeutics from California into the Canadian marketplace while rigorously investigating their safety and efficacy. Incoming CEO Bernard Fortier also brings a wealth of experience to the table as the company prepares for Phase III clinical trials of its inhaled cannabis product later this year or early next year.
For more information, visit the company’s website or CannabisFN’s company profile.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matthew Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion to creating strategic alliances. He has breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. In 2005, Mr. Nordgren received his education at the University […]
Rob is the co-founding President of Pelorus Equity Group and has more than 18 years of experience in the real estate finance industry. Since the formation of Pelorus in 2010, he has raised more than $175,000,000 in secured real estate transactions. Rob’s primary role at Pelorus Equity Group is the development of strategic alliances with […]
Crop Infrastructure is engaged in the business of investing, constructing, owning and leasing mega-greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations.
Revive Therapeutics’ cannabinoid pharmaceutical portfolio focuses on rare inflammatory areas such as liver disease.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
